Welcome to our dedicated page for Zynex SEC filings (Ticker: ZYXI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zynex Inc. filings document the regulatory record of a medical technology company that develops and sells non-invasive devices for pain management, rehabilitation, and patient monitoring. Its periodic reports and current reports have covered operating results, liquidity, billing and reimbursement matters, compliance risks, governance changes, and material events affecting the company and its subsidiaries.
Recent filings also document Zynex's Chapter 11 reorganization and public-company status changes. The record includes 8-K disclosures on bankruptcy proceedings, plan amendments and confirmation, Nasdaq delisting and OTC trading status, material agreements with government authorities, the conclusion of an SEC investigation without a recommended enforcement action, and board actions. A Form 15 reports termination or suspension of Exchange Act registration duties after the plan became effective, the prior common stock was cancelled, and new common stock was issued to the plan sponsor.
Zynex, Inc. appointed Vikram Bajaj as Chief Financial Officer and Treasurer and John Bibb as Chief Legal Officer and Secretary, effective August 18, 2025. Former CFO Dan Moorhead resigned that day and will leave the company on August 29, 2025.
Bajaj and Bibb each receive a $450,000 annual base salary and are eligible for an annual discretionary bonus targeted at 70% of base pay. Each is granted inducement equity awards with a grant date fair value of $2.5 million in restricted stock vesting after three years and $2.5 million in stock options vesting quarterly over four years, subject to continued employment and certain accelerated vesting triggers. They also receive six months of salary and health benefits plus a pro‑rated bonus if terminated without cause or for good reason. The board expanded from four to five members and elected CEO Steven Dyson as a director without additional compensation.
Zynex Inc. (ZYXI) – Form 4 filing, 29 Jul 2025. Chief Operating Officer Anna Lucsok reported two equity-compensation transactions.
- Restricted Stock Award: On 27 Jul 2025 Lucsok received 7,500 common shares under the 2017 Stock Incentive Plan. The grant vests in equal annual tranches over four years and was issued at $0 cost.
- Tax-Withholding Share Surrender: On 28 Jul 2025 the issuer withheld 3,793 shares (Code F) at an implied value of $2.56 per share to cover payroll taxes related to previously vested RSAs. This is not an open-market sale.
After the transactions, Lucsok directly holds 64,412 shares, most of which remain unvested. No derivatives were involved and there were no cash sales or purchases. The filing modestly increases insider ownership alignment but has immaterial dilution given Zynex’s overall share count. Investor impact is therefore limited and chiefly informative for governance monitoring.
Zynex announced a significant workforce reduction on June 18, 2025, cutting 86 corporate positions, representing 14% of its total workforce. The restructuring is expected to generate $5 million in annualized cost savings.
Key financial impacts include:
- Total restructuring costs estimated at $0.2 million, primarily for employee severance
- Costs to be recognized in Q2 2025
- Majority of payments expected in Q2 and Q3 2025
The company also addressed an ongoing Tricare payment suspension, noting that while they have appealed the temporary suspension, no response has been received. Zynex emphasized that the workforce reduction is part of a planned adjustment in order processing and billing strategy, unrelated to the Tricare situation.